Epitalon Compounding Pharmacy: How to Choose a Peptide Compounder

Is epitalon on any list of substances pharmacies may compound with?

Under the federal compounding framework, a state-licensed pharmacy may compound with a bulk drug substance only if it complies with a USP or National Formulary monograph, is a component of an FDA-approved drug, or appears on FDA's list of bulk substances that can be used in compounding [4]. Epitalon has no USP or National Formulary monograph, is not a component of an FDA-approved drug, and is not on FDA's pharmacy bulks list [1][2][4]. FDA's July 2026 review found no monograph in the European or Japanese pharmacopeias either, and no approved epitalon product in the United States, Canada, Australia, the UK, Belgium, Ireland, France, Norway, Germany, Spain or Italy, or authorized by the European Medicines Agency [1].

Epitalon appears in none of the three categories on FDA's list for state-licensed pharmacies and physicians (updated May 14, 2026) and in none of the three categories on FDA's list for outsourcing facilities (updated March 21, 2025) [2][3][4]. FDA's category 1 policy, under which the agency generally does not intend to act against compounders that meet its conditions, does not cover it [2][3][4]. FDA also reported that it found no pharmacy compounding epitalon and no outsourcing facility reporting it [1].

Because epitalon is on none of these lists, what a buyer can check is narrower: the conditions in the draft HHS policy, which include the ingredient's manufacturer and a certificate of analysis [7][8].

What FDA has said about epitalon in compounding

FDA's page on bulk substances that may present significant safety risks (content dated 04/22/2026) lists epitalon in the 'nominated but withdrawn' table, which holds substances previously in category 2 whose nominators withdrew them. FDA's stated concern is that it 'has not identified safety-related information regarding epitalon for the proposed route of administration', so it lacks enough information to know whether the drug would cause harm. The page also notes that injectable peptides may pose immunogenicity risk from aggregation and impurities, and that removal from category 2 was not a finding that epitalon is safe [5].

At the July 2026 review, FDA staff proposed that neither epitalon free base nor epitalon acetate be added to the pharmacy bulks list. FDA evaluated only the insomnia use; the other nominated uses, such as anti-aging and telomere lengthening, were not evaluated for lack of information. Its reasons: the substance is not well characterized, has limited historical use, has no evidence of effectiveness for insomnia and no clinical safety data, carries an immunogenicity concern for subcutaneous injection, and many FDA-approved insomnia drugs already exist. The nominated products were 10 mg/mL and 3000 microgram/mL subcutaneous injections [1].

The Pharmacy Compounding Advisory Committee reviewed epitalon on July 24, 2026 and voted in favor of adding it to the bulks list, against the staff recommendation. That vote is advice only and not binding; epitalon is not on the list, and adding it takes formal rulemaking [6][7].

What conditions does the October 2026 draft policy name?

The most specific drug-level checklist available comes from HHS's draft enforcement-discretion policy for compounding with certain peptides, filed October 28, 2026 as Federal Register document 2026-22192, with publication scheduled for October 30, 2026 and comments due two weeks after publication. It names epitalon among six peptides and covers epitalon acetate given by subcutaneous or intramuscular injection in intermittent courses. HHS says it 'does not intend to take enforcement action' against a state-licensed pharmacy, federal facility or licensed physician that compounds with it if the policy's conditions are met, for example:

• a single active ingredient
• a patient-specific prescription
• active ingredient from an FDA-registered manufacturer, with a certificate of analysis
• a label reading 'This is a compounded drug product. Not for resale.' [7][8]

Those are concrete questions to put to a pharmacy: what is in the vial, who made the raw material and can they show its certificate of analysis, whose prescription is it filling, and how is the vial labeled.

The draft is not an approval and does not put epitalon on any list. The notice states that it 'does not establish any rights for any person and is not binding on HHS or the public', and HHS may revisit it, for example if a safety signal or product quality issue arises [7]. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they reach patients [9].

What is known about epitalon's safety and dosing

FDA found no clinical study that assessed epitalon's safety [1]. Its search of the adverse-event database through December 8, 2025 and its search of the food and supplement complaint system through December 5, 2025 retrieved no epitalon reports [1]. FDA also warned that because epitalon activates telomerase and lengthens telomeres, and longer telomeres are generally linked to higher cancer risk, it has a mechanistic potential to be carcinogenic. The mouse studies of cancer and chromosome damage were too limited to show safety (one fixed dose, female mice only, short exposure) [1]. FDA found no pharmacokinetic data for epitalon [1].

There is no approved dose for epitalon [1]. Websites FDA reviewed suggest 5 mg to 10 mg per day by subcutaneous injection or orally, in cycles (one site every four months); that is marketing, not evidence. The human studies FDA found used a sublingual spray delivering about 0.5 mg per day for 20 days and a parabulbar injection beside the eye for retinitis pigmentosa [1].

An older controlled study in retinitis pigmentosa, in which epitalon was injected beside the eye, reported a 'positive clinical effect' in 90% of patients with degenerative retinal lesions; its abstract gives no sample size or design details [10]. It has not been replicated and is not a modern randomized trial. A 2026 narrative review found human evidence limited to small physiological or biomarker studies plus that older study, and no adequately powered randomized trial establishing efficacy [10][11].

On the telomere claim: adding epitalon to telomerase-negative human fetal fibroblast cultures induced telomerase activity and telomere elongation, which is a cell-culture result [12]. FDA found no study showing epitalon extends life or slows aging in people [1]. The same 2026 review described epitalon as 'biologically active but clinically unproven', with inadequate pharmacokinetic, dose-ranging and long-term safety data [11].

Claims that should make you doubt a seller

• Human telomere or anti-aging results. The telomere finding comes from cultured cells, and FDA found no study showing an effect on aging or lifespan in people [12][1].
• 'No side effects.' This is not established. It traces to a Russian-language abstract that gave no dose, route or number of people [1].
• Saying FDA, its advisory committee or HHS has approved epitalon or made it legal to compound. The committee only advised, FDA staff recommended against listing it, and the HHS policy is a draft, non-binding statement about enforcement discretion [7][1].
• Treating epithalamin studies as epitalon studies. Epithalamin is a polypeptide extract of animal pineal gland; epitalon is a synthetic four-amino-acid peptide, and FDA treats them as different substances [1].
• Citing the orphan drug designation without the withdrawal. Epitalon was designated for retinitis pigmentosa on September 2, 2010, and the designation was withdrawn on January 6, 2016 [1].
• Research-use-only vials of 10 mg to 50 mg, capsules and oral sprays sold online and promoted as an anti-aging 'fountain of youth' peptide. A 2015 analysis also found epitalon in two illegal pharmaceutical preparations sold for cancer, old age and retinitis pigmentosa [1][13].

Frequently asked questions